Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Clinical Trial ID NCT03509246

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03509246

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Integrated genomic analyses of ovarian carcinoma. Nature 2011 47.72
2 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007 3.54
3 Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A 2013 1.22
4 FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy. Clin Cancer Res 2015 1.22
Next 100